<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00100724</url>
  </required_header>
  <id_info>
    <org_study_id>VAX006</org_study_id>
    <nct_id>NCT00100724</nct_id>
  </id_info>
  <brief_title>Trial of rPA-102 Vaccine in Healthy Adult Volunteers</brief_title>
  <official_title>A Phase 2 Multi-Center, Randomized Dose-Finding Trial of rPA-102 Vaccine in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VaxGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>VaxGen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and immunogenicity of rPA102 vaccine given&#xD;
      intramuscularly at 0 and 4 weeks over 2 dose ranges and 4 adjuvant levels.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date>July 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and immune response to vaccine.</measure>
  </primary_outcome>
  <enrollment>480</enrollment>
  <condition>Anthrax</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rPA102</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to understand the study and give written informed consent. A signed informed&#xD;
             consent must be in place before the initiation of any study interventions.&#xD;
&#xD;
          -  Healthy male or female aged 18-55 years old (inclusive) without significant physical&#xD;
             or clinical laboratory abnormalities.&#xD;
&#xD;
          -  Two intact upper arms with sufficient intramuscular (IM) tissue in the deltoid region&#xD;
             for vaccine administration.&#xD;
&#xD;
          -  For females, negative serum pregnancy test at screening and agreement to use adequate&#xD;
             birth control during the first 2 months of the study.&#xD;
&#xD;
          -  Willingness and ability to return for all follow-up visits and blood draws for the&#xD;
             duration of the study.&#xD;
&#xD;
          -  Willingness to complete the Volunteer Diary and to report concomitant medications and&#xD;
             adverse events (AEs) to the study site monitors during the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of, or known exposure to any form of B. anthracis or any anthrax&#xD;
             immunization.&#xD;
&#xD;
          -  Member of the Armed Services (Active Duty or Reserve) since 1990, with history of&#xD;
             previous anthrax vaccination.&#xD;
&#xD;
          -  Employment in an industry involved in contact with ruminant animals, veterinary&#xD;
             sciences, or other exposure to B. anthracis, or emergency first responders.&#xD;
&#xD;
          -  Expected to be noncompliant with study visits or planning to move within 12 months.&#xD;
&#xD;
          -  Body mass index of &gt;35 or &lt;19.&#xD;
&#xD;
          -  Known allergy to aluminum hydroxide, kanamycin, or any other aminoglycoside&#xD;
             antibiotics (such as gentamicin).&#xD;
&#xD;
          -  Pregnancy (positive urine pregnancy test within 24 hours prior to vaccination), or&#xD;
             lactation.&#xD;
&#xD;
          -  HIV positive (by history or screening ELISA).&#xD;
&#xD;
          -  Hepatitis B or C positive (by history or screening HBsAg/anti-HCV ELISA).&#xD;
&#xD;
          -  Active or past internal organ, hematologic malignancy, or metastatic cutaneous&#xD;
             malignancy.&#xD;
&#xD;
          -  History of, or current autoimmune disease, including but not limited to systemic lupus&#xD;
             erythematosus, scleroderma, and polyarteritis.&#xD;
&#xD;
          -  Immunodeficiency or unstable medical condition as determined by baseline medical&#xD;
             history, physical exam, and laboratory assessment.&#xD;
&#xD;
          -  Received or plans to receive licensed live vaccines within 30 days of study&#xD;
             vaccination.&#xD;
&#xD;
          -  Received or plans to receive licensed killed vaccines within 14 days of study&#xD;
             vaccination.&#xD;
&#xD;
          -  Received or plans to receive immunoglobulin or other blood products within 60 days of&#xD;
             study vaccination.&#xD;
&#xD;
          -  Received or plans to receive experimental drugs/vaccines within 30 days prior to, and&#xD;
             for the duration of the study.&#xD;
&#xD;
          -  Received or plans to receive systemic immunosuppressive therapy, radiation therapy, or&#xD;
             high-dose inhaled steroids within 30 days of study vaccination.&#xD;
&#xD;
          -  Use of systemic chemotheraphy within 5 years prior to study.&#xD;
&#xD;
          -  History of Guillain-Barre Syndrome.&#xD;
&#xD;
        In addition to the conditions listed above, the following may qualify as a reason to&#xD;
        exclude a volunteer from the study: fever along with moderate or serious illness within 3&#xD;
        days of vaccination or any condition that, in the opinion of the investigator, would render&#xD;
        vaccination unsafe or would interfere with the study evaluations. Pending resolution of&#xD;
        these symptoms, a volunteer may be reconsidered for vaccination.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA Ctr for Vaccine Research, LA Biomedical Research Institute</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Children's Clinic, Pediatric Infectious Disease</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky, Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University, Bloomberg School of Public Health</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic College of Medicine</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University, SoLUtions</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Unit, University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Clinical Trials Int'l, Inc. (PCTI)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Physicians Research, Inc.</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont College of Medicine, Vermont Vaccine Evaluation Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2006</verification_date>
  <study_first_submitted>January 5, 2005</study_first_submitted>
  <study_first_submitted_qc>January 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2005</study_first_posted>
  <last_update_submitted>January 10, 2006</last_update_submitted>
  <last_update_submitted_qc>January 10, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2006</last_update_posted>
  <keyword>Anthrax</keyword>
  <keyword>rPA102</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anthrax</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

